In the high-stakes world of pharmaceutical development, the journey from laboratory bench to bedside is notoriously precarious. While the industry celebrates blockbuster approvals, a silent crisis looms in the shadows of corporate boardrooms: more than 5,000 potential rare disease treatments currently sit gathering dust on pharmaceutical shelves. These are not necessarily failed compounds; they are often viable, well-researched therapies that have been sidelined due to shifting corporate strategies, mergers, or simple commercial prioritization.
Annette Bakker, PhD, CEO of the Children’s Tumor Foundation (CTF), has made it her mission to turn this "pipeline of discarded potential" into a lifeline for patients. By positioning her organization as a proactive drug discovery engine, Bakker is proving that nonprofits can bridge the gap between abandoned corporate assets and the patients who desperately need them.
The Anatomy of a Shelved Asset
To understand why thousands of drugs are sitting idle, one must look at the economics of modern drug discovery. Large pharmaceutical companies frequently acquire smaller biotech firms to secure a single "star" candidate. In the consolidation that follows, the remaining portfolio of the acquired company—often containing promising, albeit niche, drug candidates—is frequently deprioritized or shelved.
"Shelved assets are our focus because a shelved asset has already undergone a lot of development," explains Dr. Bakker. "A company has maybe already spent hundreds of millions of dollars on them, and they are now written off as a loss. What if we could take those and put them right into clinical trials? We could win all those years of preclinical and toxicology and go into clinical almost immediately."
The tragedy, according to industry experts, is that many of these assets possess robust preclinical data or even successful Phase 1 trials. When a biotech company fails or is absorbed, the critical data associated with these assets often becomes inaccessible, effectively burying years of scientific progress.
Chronology of a Success Story: The Path to Gomekli
The CTF’s model is best illustrated by its landmark intervention in the development of neurofibromatosis (NF) treatments. NF is a complex group of genetic conditions that trigger the growth of tumors on nerves throughout the body.
2017: The Strategic Spin-off
Recognizing the potential of specific MEK inhibitors for NF patients, Dr. Bakker engaged with leadership at Pfizer. Through persistent advocacy, she convinced the pharmaceutical giant to license a shelved asset to a newly formed spin-off, SpringWorks Therapeutics. This entity was specifically structured to focus on these neglected candidates.
2023: Regulatory Milestone
The efforts culminated in the FDA approval of Gomekli (nirogacestat), the first systemic treatment for adults with progressing, symptomatic desmoid tumors. While the initial focus was NF, the foundation’s role in navigating the corporate landscape allowed the drug to finally reach the market.
2024: Industry Validation
The success of the SpringWorks model was cemented when Merck KGaA acquired the company for $3.4 billion. This acquisition served as a powerful signal to the investment community: there is significant, untapped value in the "discarded" portfolios of Big Pharma.
Supporting Data: The Rare Disease "Complexity Gap"
Rare disease drug discovery is exponentially more difficult than standard drug development. The sheer rarity of these conditions—such as NF, which affects roughly 1 in 2,000 individuals—creates a "Complexity Gap" that hampers traditional clinical trial recruitment.
The Recruitment Challenge
In large-scale trials for common conditions like hypertension or diabetes, thousands of patients are readily accessible. In the rare disease space, a single trial might require patients from across several continents, driving up costs and slowing timelines.
The CTF Ecosystem
To counter these obstacles, the CTF has developed a robust preclinical hub. This ecosystem acts as a centralized repository of preclinical models and patient data. By maintaining a deep, global network of patients, the foundation effectively eliminates the primary bottleneck in rare disease drug development: the delay in finding and enrolling the right participants.
"Everything you do in drug discovery is ten times harder in rare disease," Bakker notes. "But by creating an ecosystem that ensures we are ready the moment we acquire an asset, we turn a cumbersome process into an efficient, accelerated pipeline."
The Institutional Hurdle: Seeking Corporate Champions
Despite the success with Pfizer, the path forward remains fraught with cultural and institutional inertia. Bakker admits that the current model is difficult to scale because it relies on finding "champions" within large organizations—individuals like Pfizer’s former executives Freda Lewis-Hall and Lara Sullivan, who were willing to listen to the patient perspective and pivot their corporate strategy.
"We are looking for these champions in other companies that are willing to work with us, but the pharma companies we are calling are not always opening the door," says Bakker. The challenge is not just technical; it is bureaucratic. In many cases, the legal and intellectual property barriers surrounding a "shelved" drug are so thick that even the original patent holders are hesitant to release the asset to a nonprofit.
Implications for the Future of Drug Discovery
The work being pioneered by the Children’s Tumor Foundation carries profound implications for the future of medicine.
1. A New Role for Patient Advocacy Groups
Nonprofits are moving from being passive fundraisers to active, sophisticated participants in the R&D process. By leveraging their deep knowledge of the patient population and their ability to de-risk projects, these groups are becoming essential partners for biotech companies.
2. The "Circular Economy" of Pharma
There is a growing argument for the creation of an "asset exchange" for shelved drugs. Just as industries move toward circular economies to reduce waste, the pharmaceutical industry could benefit from a centralized, transparent platform where shelved assets can be audited by nonprofits and academic researchers before they are permanently written off.
3. Rethinking Commercial Value
The $3.4 billion acquisition of SpringWorks suggests that what pharma views as a "loss" can be a multi-billion-dollar success. This valuation gap encourages a shift in how companies account for their R&D failures. If a company knows they can divest an asset to a nonprofit for a potential milestone payment, they may be more inclined to keep data and compounds in a "warm" state rather than burying them entirely.
Conclusion: The Moral and Economic Imperative
The existence of 5,000 shelved rare disease treatments is a staggering statistic that represents both a moral failure and an economic opportunity. For the patients suffering from these conditions, every day that a potential treatment sits on a shelf is a day of lost quality of life.
The Children’s Tumor Foundation is providing a roadmap for how to change this reality. By acting as a bridge—connecting the rigorous, large-scale science of the pharmaceutical industry with the urgent, patient-centric focus of the nonprofit sector—they are proving that innovation does not always require a new discovery. Sometimes, it simply requires the courage to look back at what has been left behind.
As the industry moves forward, the success of the CTF model may well define the next decade of rare disease research. If more "champions" emerge within the halls of Big Pharma to join this effort, we may soon see a renaissance of "forgotten" medicines, transforming corporate write-offs into the next generation of life-saving therapies.
About the Author
